Technology
Ai for Every Step of Drug Discovery and Development. This is how BIOPTIC will revolutionize pharma:
Generative AI pinpoints exceptional drug candidates
In the last year, BIOPTIC has discovered several high-potential molecules. We accomplished this by building a Ligand-Based Model B1– to screen 100B compounds and focus on targets with known binders – and a Structure-Based Model B2 to discover binders to completely new, previously unseen targets.
Our Ligand-Based Model B1 makes screening ultra-large libraries almost unthinkably cheap. Our Structure-Based Model B2 outperforms AlphaFold3 and allows us to bypass the protein structure step, taking only the protein sequence and a SMILES string and outputting accurate activity scores. That means ~1700 molecules/sec on a single NVIDIA T4 GPU.
Vertical AI agents automate the business of drug development
BIOPTIC uses LLM-based agentic AI to de-risk and speed up the costly and laborious latter stages of drug development. AI agents act as digital employees, able to think like biologists and medicinal chemists, pharmacologists and clinicians, BD analysts and supply chain specialists, health economists and market strategists — all at once.
Your word, their command
Simply set them on a task and BIOPTIC agents will seek out data at an unimaginable speed, volume, and level of accuracy.
BIOPTIC Agent, help me with market intelligence
“Identify the most commonly used endpoints in plaque psoriasis over the past 5 years and analyze reasons for their selection.”
BIOPTIC Agent, help me with in-licensing
“Analyze trial success and safety outcomes for Retatrutide and compare them with all competitors currently in trials.”
BIOPTIC Agent, help me with commercialization
“Find newly launched dermatology drugs showing rapid first-year growth globally and compare them to generics available in Australia.”
A lookout and a guide
BIOPTIC vertical agents don’t sit idly by, waiting for you to tell them what to do. They work autonomously, continously monitoring a vast and diverse data landscape and bringing back critical insights.
- Agents track company websites, conference materials, analyst reports, scientific publications, clinical trial updates, and much more from around the globe.
- Agents warn you of regulatory changes and market shifts, or developments with specific molecules - or whole therapeutic areas - that require your attention.
- Agents proactively suggest actionable steps, like X or Y.
No hallucinations
There's a reason other generative AIs hallucinate — they’re trained to reproduce patterns found across huge amounts of internet text, but don’t actually verify their output.
BIOPTIC agents are only trained on clean, pharma-specific data and constantly check themselves to ensure accuracy. This is how we get it right:
- Agents work directly with hundreds of curated data sources - including clinical trials, patents, market deals and reports - and are able to use patent and clinical trial search.
- Agents double-check themselves and other agents, using a rigorous QA process where they test their results against known benchmarks and cite their sources.
- We evaluate and tune our agents on specifically collected data for clinical trial outcome prediction, due diligence Q&A, and anti-hallucinations reasoning.
- We give humans the final say, creating a feedback loop that ensures high quality results.
Augmenting humans, not replacing them
Our AI agents are designed to work in collaboration with people, guided and improved by their human partners. Our goal is to automate routine tasks and allow humans to focus on interacting with other humans, creating partnerships and deals, and making critical scientific and business decisions based on the best data possible.
BIOPTIC partners with Bio Hubs and builds our own Hub and Spokes
Our vision is to become a fully autonomous hub and spoke pharma, with generative AI discovering molecules to fill each spoke, and agentic AI automating business processes in the hub. Scientists in the spokes would be able to focus on science, while executives in the hub could steer the AI-run ship.
We’re not there yet.
But we have partnered with several hub and spoke pharma companies and major US universities to bring agentic AI to biotech. If you’d like to be a part of the AI revolution, get in touch.
Get in touch
Whether you’re a researcher, potential partner, or just curious about what we’re building, drop us a message. Explore how we can push the boundaries of science and discovery.